EP3027061A1 - Souche de lactobacillus rhamnosus régulatrice du métabolisme lipidique - Google Patents
Souche de lactobacillus rhamnosus régulatrice du métabolisme lipidiqueInfo
- Publication number
- EP3027061A1 EP3027061A1 EP14722774.8A EP14722774A EP3027061A1 EP 3027061 A1 EP3027061 A1 EP 3027061A1 EP 14722774 A EP14722774 A EP 14722774A EP 3027061 A1 EP3027061 A1 EP 3027061A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- lactobacillus rhamnosus
- strain
- rhamnosus strain
- angptl4
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 16
- 230000037356 lipid metabolism Effects 0.000 title description 4
- 230000001105 regulatory effect Effects 0.000 title 1
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 10
- 238000009825 accumulation Methods 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 5
- 230000007170 pathology Effects 0.000 claims abstract description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 208000008589 Obesity Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 206010033307 Overweight Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 101150054149 ANGPTL4 gene Proteins 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 description 19
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 5
- 102000043296 Lipoprotein lipases Human genes 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 230000003816 axenic effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 102000000536 PPAR gamma Human genes 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101000693095 Mus musculus Angiopoietin-related protein 4 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000006501 Angiopoietin-like Proteins Human genes 0.000 description 1
- 108010019425 Angiopoietin-like Proteins Proteins 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193452 Clostridium tyrobutyricum Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002891 anorexigenic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Definitions
- the invention relates to the use of probiotics to regulate lipid metabolism.
- BMI body mass index
- Obesity is an important factor in the development of diseases such as hypertension, type II diabetes, cardiovascular disease, liver disease and certain cancers, and is rapidly becoming a major public health problem.
- the number of obese people in the world has more than doubled since 1980. In 2008, more than 1.4 billion adults were overweight, and among these, more than 200 million men and almost 300 million women were obese.
- ANGPTL4 protein angiopoietin like 4
- FIAF fasting induced adipose factor
- PGAR PPAR- ⁇ induced angiopoietin-related protein
- HFARP hepatic fibrinogen / angiopoietin reiated protein
- ANGPTL4 is a target gene for PPARs (peroxisome proliferator-activated receptors) nuclear receptors, including PPAR- ⁇ in TA and colon, and PPAR-cc in the liver and small intestine.
- PPARs peroxisome proliferator-activated receptors
- ANGPTL4 inhibits the activity of lipoprotein lipase (LPL) by promoting the dissociation of active LPL dimers into inactive monomers (SUKONINA et al., Proc Natl Acad Sci USA, 103, 17450-5, 2006), which leads to the mobilization of triglycerides as a source of energy in favor of the peripheral organs, and the limitation of the excessive storage of fats in organs such as in adipose tissue, the heart and macrophages.
- LPL lipoprotein lipase
- ANGPTL4 improved glucose tolerance in obese mice with type II diabetes (XU et al., Proc Natl Acad Sci USA, 102, 6086-91, 2005) but also induced in this model animal hyperlipidemia in the short term. In humans, an inverse correlation between plasma ANGPTL4 levels, adiposity, or increased blood glucose has been reported (ROBCIUC et al., J Lipid Res, 51, 824-31, 2010; ROBCIUC et al. , J Lipid Res, 52, 1575-82, 201 1).
- ANGTPL4 protein anorexigenic effect (KIM et al., Diabetes, 59, 2772-80, 2010) or a decrease in inflammation caused by saturated dietary lipids (LICHTENSTEIN and al., Cell Metab, 12, 580-92, 2010).
- ANGPTL4 has been shown to play an important role in controlling the expression of ANGPTL4 in the small intestine.
- the level of ANGPTL4 expression in the small intestine is higher in axenic mice than in conventional mice, and colonization of axenic mice reduces its level of expression (BACKHED et al., Proc Natl Acad Sci USA, 101, 15718-23, 2004).
- LPL Lipoprotein Lipase
- Lactobacillus paracasei F19 induces the intestinal expression of ANGPTL4 (PPARs dependent) resulting in vivo by a decrease in fat mass (ARONSSON et al., PLoS One, 5, 2010).
- ANGPTL4 PPARs dependent
- a commensal bacterium, Clostridium tyrobutyricum induces strong expression of ANGPTL4 during colonization of axenic mice (KORECKA, et al., Am J. Physiology Gastrointest Liver Physiol, in press, 2013).
- the present invention relates to the use of the strain Lactobacillus rhamnosus CNCM 1-4317 or a composition containing said strain, for preventing or reducing excessive accumulation of fat in adipocytes and metabolic consequences and / inflammatory conditions, such as insulin resistance in a subject or chronic inflammation.
- said subject is a mammal, which may be an animal or a human.
- the present invention includes the CNCM 1-4317 strain of
- Lactobacillus rhamnosus or a composition containing said strain for use as a medicament in the treatment, prevention, or mitigation of a condition due to excessive accumulation of body fat and / or insulin resistance.
- pathologies resulting from excessive body fat accumulation are overweight, obesity and related disorders, such as metabolic syndrome, type II diabetes, non-alcoholic fatty liver, hypertension, high blood pressure, chronic inflammation, etc.
- the present invention also encompasses the non-therapeutic use of the CNCM 1-4317 strain to prevent or reduce excessive body fat accumulation in a subject for cosmetic purposes.
- Lactobacillus rhamnosus strain CNCM 1-4317 can be used in the form of whole bacteria which can be alive, or non-living, for example heat-inactivated.
- she can be used in the form of a bacterial lysate, or in the form of bacterial fractions; the bacterial fractions suitable for this use are in particular supernatants of cultures of the CNCM 1-4317 strain.
- compositions used in the present invention may be in any form suitable for administration, particularly oral administration. This includes, for example, semi-solid, liquid and powder formulations.
- the composition may typically comprise from 10 5 to 10 13 colony forming units (cfu), in particular at least 10 6 cfu, preferably at least 10 7 cfu, preferably at least 10 8 cfu. cfu, and most most preferably at least 10 9 cFU per gram dry weight of the composition.
- cfu colony forming units
- this generally corresponds to from 10 4 to 10 12 cfu, preferably at least 10 5 cfu, more preferably at least 10 6 cfu, advantageously at least 10 7 cfu, and quite exactly preferred at least 10 9 cfu / ml.
- compositions for use in the present invention are nutritional compositions, including food products and especially dairy products. These nutritional compositions also include dietary supplements and functional foods.
- a "dietary supplement” means a product made from compounds commonly used in food, but which is in the form of tablets, powder, capsules, potion or any other form not usually associated with food, and which has beneficial effects for health.
- a “functional food” is a food that, in addition to its nutritional properties, also has beneficial effects on health.
- dietary supplements and functional foods can have a physiological effect - protective or curative - against a disease, for example against a chronic disease.
- compositions suitable for use in the present invention are pharmaceutical or cosmetic compositions.
- compositions of the invention may also comprise, besides the CNCM 1-4317 strain, one or more other strain (s) of lactic acid bacteria, probiotic or otherwise, for example one or more bacterial strain (s). selected from the genera Lactobacillus, Lactococcus, Streptococcus, and Bifidobacteria.
- this (these) other strain (s) may include one or more strain (s) of Streptococcus thermophilus, and / or one or more strain (s) of Lactobacillus bulgaricus.
- ANGPTL4 The effect of several bacterial strains belonging to the L.paracasei and L.rhamnosus species on the expression of the ANGPTL4 gene was measured in cancerous HT29 cancer cells, and compared with that of rosiglitazone (PPAR ⁇ receptor agonist, known to increase very strongly the expression of ANGPTL4).
- the HT29 cells were cultured in DMEM medium (Lonza®) supplemented with 20% fetal calf serum (FCS) (Lonza®), 2mM glutamine (Sigma®), IX non-essential amino acids (NAA) ( Invitrogen®) and 50U / ml penicillin streptomycin (Lonza®) mixture in an environment containing 10% CO 2 at 37 ° C.
- the cells were detached with trypsin-versene EDTA (Lonza®) and plated in a 6-well plate. 625,000 cells were deposited per well and cultured for 48 hours in DMEM medium without antibiotic.
- the medium was changed before contacting cells for 6h with bacterial suspensions, DMEM (negative control) or rosiglitazone (positive control).
- DMEM negative control
- rosiglitazone positive control
- the cell cultures were then rinsed with PB S (Lonza®) before extracting RNA.
- Rosiglitazone (Cayman chemical®) was prepared in DMSO and diluted in cell culture medium. This preparation was brought into contact with the cells at a final concentration of 10 ⁇ .
- the bacterial suspensions were then added to the cells at 20% of the final volume.
- RNA samples were extracted with the kit "RNeasy mini kit” (Qiagen®) according to the supplier's instructions.
- the RNA was assayed with nanodrop and an agarose gel was made to determine the quality of the RNAs.
- the cDNA synthesis was performed from the final RNA using the High Capacity cDNA reverse transcription kit (Applied Biosystems®) and the T100 Thermal Cycler device (Biorad®) according to supplier's instructions.
- the cDNAs obtained were assayed with nanodrop and preparations at 10 ng / ⁇ l were made in water nuclease free (Ambion®) for RTqPCR.
- RTqPCRs were performed using the "Taqman® gene expression master” reagents (Applied Biosystems®) with the device (ABI PRISM 7000 - Applied Biosystems®) according to the supplier's instructions.
- mice C57BL / 6 germ-free mice aged 7 to 11 weeks were maintained under standard diet (R 03-40, SAFE).
- RNAlater stabilizing reagent
- Tissue RNA was extracted using the RNeasy kit mini-kit (Qiagen) and ⁇ cDNA synthesized from 1 ⁇ g RNA using the High Capacity Kit cDNA Reverse Transcription Kit (Applied Biosystems) .
- the cDNAs were diluted to 203 ⁇ 4 / ⁇ 1 and the RTqPCRs performed with a final volume of 25 ⁇ 1 using Taqman probes (Life Technologies) and the ABI Prism 7700 thermocycler (Applied Biosystem) according to the supplier's recommendations.
- the results were normalized using 2 control genes (GAPDH and ⁇ -actin).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1353600A FR3004621B1 (fr) | 2013-04-19 | 2013-04-19 | Souche de lactobacillus rhamnosus regulatrice du metabolisme lipidique |
PCT/IB2014/060841 WO2014170879A1 (fr) | 2013-04-19 | 2014-04-18 | Souche de lactobacillus rhamnosus régulatrice du métabolisme lipidique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3027061A1 true EP3027061A1 (fr) | 2016-06-08 |
Family
ID=49003844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14722774.8A Withdrawn EP3027061A1 (fr) | 2013-04-19 | 2014-04-18 | Souche de lactobacillus rhamnosus régulatrice du métabolisme lipidique |
Country Status (6)
Country | Link |
---|---|
US (1) | US20160074444A1 (es) |
EP (1) | EP3027061A1 (es) |
FR (1) | FR3004621B1 (es) |
MX (1) | MX2015014450A (es) |
RU (1) | RU2015146979A (es) |
WO (1) | WO2014170879A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113046276B (zh) * | 2021-04-30 | 2022-03-18 | 澳优乳业(中国)有限公司 | 一种母乳源鼠李糖乳杆菌及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7001756B1 (en) * | 2004-02-19 | 2006-02-21 | Genmont Biotech Inc. | Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity |
KR100686557B1 (ko) * | 2004-08-16 | 2007-02-23 | 씨제이 주식회사 | 체지방 저하 기능성 락토바실러스 람노서스와 이를 함유한 식품 |
EP2022502A1 (en) * | 2007-08-10 | 2009-02-11 | Nestec S.A. | Lactobacillus rhamnosus and weight control |
EP2216035A1 (en) * | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus rhamnosus CNCM I-4096 and weight control |
FI123157B (fi) * | 2009-05-12 | 2012-11-30 | Valio Oy | Probioottien uusi käyttö |
WO2011148219A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving the enteric nervous system |
-
2013
- 2013-04-19 FR FR1353600A patent/FR3004621B1/fr active Active
-
2014
- 2014-04-18 US US14/784,760 patent/US20160074444A1/en not_active Abandoned
- 2014-04-18 MX MX2015014450A patent/MX2015014450A/es unknown
- 2014-04-18 EP EP14722774.8A patent/EP3027061A1/fr not_active Withdrawn
- 2014-04-18 RU RU2015146979A patent/RU2015146979A/ru not_active Application Discontinuation
- 2014-04-18 WO PCT/IB2014/060841 patent/WO2014170879A1/fr active Application Filing
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2014170879A1 * |
Also Published As
Publication number | Publication date |
---|---|
MX2015014450A (es) | 2016-05-05 |
US20160074444A1 (en) | 2016-03-17 |
RU2015146979A (ru) | 2017-05-24 |
WO2014170879A1 (fr) | 2014-10-23 |
FR3004621A1 (fr) | 2014-10-24 |
FR3004621B1 (fr) | 2015-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zoumpopoulou et al. | Dairy probiotics: Beyond the role of promoting gut and immune health | |
US10286026B2 (en) | Probiotic fermented cereal compositions and methods for treatment of gastrointestinal diseases caused by pro-inflammatory bacteria | |
TWI572354B (zh) | 抑制發炎之組成物 | |
Long et al. | Lactobacillus plantarum KFY04 prevents obesity in mice through the PPAR pathway and alleviates oxidative damage and inflammation | |
WO2012014971A1 (ja) | メタボリックシンドローム改善効果を有する乳酸菌 | |
JP6479768B2 (ja) | 新規ラクトバチラス・パラカゼイ株 | |
WO2014009330A1 (fr) | Nouvelle souche de lactobacillus crispatus | |
ES2675309T3 (es) | Uso de una cepa de Lactobacillus rhamnosus para reducir la ganancia de peso y/o la resistencia a la insulina | |
Holowacz et al. | A multispecies Lactobacillus-and Bifidobacterium-containing probiotic mixture attenuates body weight gain and insulin resistance after a short-term challenge with a high-fat diet in C57/BL6J mice | |
US9855304B2 (en) | Lactobacillus rhamnosus strain for reducing body fat accumulation | |
JP5036020B2 (ja) | 腎周囲脂肪蓄積抑制剤 | |
Zhang et al. | Anti-fatigue activities of γ-aminobutyric acid-enriched soymilk in an acute exercise-treated mouse model via regulating AMPK/PGC-1α pathway | |
EP3040070A1 (en) | Dietary methods using lactobacillus paracasei subsp. paracasei f19 as nape-pld gene carrier for producing on demand pea or oea and relative biological dietary compositions thereof | |
EP3027061A1 (fr) | Souche de lactobacillus rhamnosus régulatrice du métabolisme lipidique | |
JP2022506081A (ja) | ラクトバチルス(lactobacillus)を含む代謝的健康のためのプロバイオティクス補助食品 | |
WO2022151669A1 (en) | Lactobacillus amylovorus lam1345 isolate, composition including the same and use thereof | |
HUE027121T2 (en) | Preparations containing Saccharomyces boulardii and superoxide dismutase for the treatment of obesity | |
AU2013201442B2 (en) | Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors | |
EP3889250A1 (en) | Phascolarctobacterium faecium for use in the prevention and treatment of obesity and its comorbidities | |
FR2964037A1 (fr) | Utilisation d’une souche probiotique gm-080 dans le traitement de l’inflammation cardiaque et de l’apoptose cardiaque | |
FR3138770A1 (fr) | Ensemble de parties destine a moduler le microbiote intestinale, reduire la prise de poids et le stockage des graisses dans le foie | |
WO2024105265A1 (fr) | Limosilactobacillus mucosae et désordres nécessitant un accroissement du niveau de glp-1 | |
Sannetti et al. | Dietary methods using lactobacillus paracasei subsp. paracasei f19 as nape-pld gene carrier for producing on demand pea or oea and relative biological dietary compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151119 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20171214 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180425 |